Akero Therapeutics (AKRO) Price & Analysis

Compare

610 Followers

AKRO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$21.34 - $58.40

Previous CloseN/A

Volume136.04K

Average Volume (3M)992.43K

Market Cap

$3.85B

Enterprise Value$3.66B

Total Cash (Recent Filing)$742.32M

Total Debt (Recent Filing)$37.19M

Price to Earnings (P/E)―

Beta1.20

Next Earnings

Nov 12, 2025

EPS Estimate

-0.92

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.86

Shares Outstanding79,988,976

10 Day Avg. Volume843,587

30 Day Avg. Volume992,433

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.95

Enterprise Value/Revenue913.88K

Enterprise Value/Gross Profit3.66M

Enterprise Value/Ebitda-13.09

Forecast

1Y Price Target

$72.83

Price Target Upside51.13% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe more impactful catalyst for Akero is coming with topline data from SYNCHRONY Histology, a 52-week trial in biopsy-confirmed F2/3 patients; if positive, data from the trial will support accelerated approval in the US.

Competitive PositioningThe discontinuation of zalfermin by Novo Nordisk leaves Akero's EFX in a strong competitive position in the MASH market.

Market PotentialThere is currently only one FDA approved treatment for F2/F3 MASH, highlighting the potential for Akero's EFX in addressing an unmet need.

Bears Say

Financial ChallengesA reported net loss of $70.5M in 2Q25 reflects financial challenges for the company.

Risk FactorsEFX's AEs are consistent with the known class effects of FGF21 analogs – primarily mild to moderate transient GI events.

Akero Therapeutics News

Akero Therapeutics’ efruxifermin shows efficacy in Phase 2b MASH, fibrosis trial

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet...

15d ago

AKRO

Video: Why Akero Therapeutics Is Trading Higher Today

The Fly has brought its to-the-moment stock market reporting to YouTube! Listen and subscribe. Published first on TheFly...

23d ago

NVO

AKRO

Morgan Stanley says zalfermin discontinuation has positive readthrough for Akero

Morgan Stanley notes that Novo Noridisk (NVO) announced along with reporting Q2 results this morning that the company...

23d ago

NVO

AKRO

Coinbase downgraded, Spotify upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

25d ago

AVB

BAX

Akero Therapeutics initiated with a Buy at TD Cowen

TD Cowen initiated coverage of Akero Therapeutics (AKRO) with a Buy rating and $76 price target The firm...

25d ago

AKRO

Akero Therapeutics’ Efruxifermin Study: A Potential Game-Changer for NASH Treatment

Akero Therapeutics (($AKRO)) announced an update on their ongoing clinical study. Akero Therapeutics is conducting a Phase 3...

9d ago

AKRO

Akero Therapeutics’ Phase 3 NASH Study: A Potential Game-Changer?

Akero Therapeutics (($AKRO)) announced an update on their ongoing clinical study. Akero Therapeutics is conducting a Phase 3...

10d ago

AKRO

Strong Financial Position and Promising Clinical Developments Support Buy Rating for Akero Therapeutics

Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on Akero Therapeutics, retaining the price target of...

18d ago

AKRO

Akero Therapeutics Advances in MASH Treatment Development

Akero Therapeutics ( ($AKRO) ) has released its Q2 earnings. Here is a breakdown of the information Akero...

21d ago

AKRO

Ritu Baral Recommends Buy Rating for Akero Therapeutics Amid Promising Clinical Trials and Strong Financial Position

Analyst Ritu Baral of TD Cowen maintained a Buy rating on Akero Therapeutics, retaining the price target of...

21d ago

AKRO

Akero Therapeutics Positioned as Leader in MASH Treatment with Efruxifermin Advancements

Michael Ulz, an analyst from Morgan Stanley, maintained the Buy rating on Akero Therapeutics. The associated price target...

23d ago

AKRO

AKRO Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Akero Therapeutics (AKRO) is scheduled to report 2nd quarter earnings on 08/08/2025. Regarding Q2 estimates, Wall Street analysts...

23d ago

AKRO

Akero Therapeutics Advances Efruxifermin Study for NASH Treatment

Akero Therapeutics (($AKRO)) announced an update on their ongoing clinical study. Akero Therapeutics is conducting a Phase 3...

28d ago

AKRO

Akero Therapeutics Advances Phase 3 Study on Efruxifermin for NASH/MASH Cirrhosis

Akero Therapeutics (($AKRO)) announced an update on their ongoing clinical study. Akero Therapeutics is conducting a Phase 3...

1M ago

AKRO

AKRO FAQ

What was Akero Therapeutics Inc’s price range in the past 12 months?

Akero Therapeutics Inc lowest stock price was $21.34 and its highest was $58.40 in the past 12 months.

What is Akero Therapeutics Inc’s market cap?

Akero Therapeutics Inc’s market cap is $3.85B.

When is Akero Therapeutics Inc’s upcoming earnings report date?

Akero Therapeutics Inc’s upcoming earnings report date is Nov 12, 2025 which is in 75 days.

How were Akero Therapeutics Inc’s earnings last quarter?

Akero Therapeutics Inc released its earnings results on Aug 08, 2025. The company reported -$0.86 earnings per share for the quarter, beating the consensus estimate of -$0.917 by $0.057.

Is Akero Therapeutics Inc overvalued?

According to Wall Street analysts Akero Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Akero Therapeutics Inc pay dividends?

Akero Therapeutics Inc does not currently pay dividends.

What is Akero Therapeutics Inc’s EPS estimate?

Akero Therapeutics Inc’s EPS estimate is -0.92.

How many shares outstanding does Akero Therapeutics Inc have?

Akero Therapeutics Inc has 79,988,976 shares outstanding.

What happened to Akero Therapeutics Inc’s price movement after its last earnings report?

Akero Therapeutics Inc reported an EPS of -$0.86 in its last earnings report, beating expectations of -$0.917. Following the earnings report the stock price went up 0.02%.

Which hedge fund is a major shareholder of Akero Therapeutics Inc?

Currently, no hedge funds are holding shares in AKRO

Akero Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-31.14%

Trailing 12-Months

Asset Growth

28.22%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Akero Therapeutics Inc

Akero Therapeutics (AKRO) is a clinical-stage biopharmaceutical company focused on developing and commercializing transformative treatments for patients with serious metabolic diseases. The company's primary focus is on nonalcoholic steatohepatitis (NASH), a severe form of nonalcoholic fatty liver disease. Akero's lead product candidate, Efruxifermin (EFX), is a novel Fc-FGF21 fusion protein designed to address the underlying causes of NASH by reducing liver fat, inflammation, and fibrosis.

Akero Therapeutics (AKRO) Earnings & Revenues

Historic Earnings Reports

AKRO Stock 12 Month Forecast

Average Price Target

$72.83

▲(51.13% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"$17","34":"$34","51":"$51","68":"$68","85":"$85"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":84,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$84.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":72.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$72.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$60.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,34,51,68,85],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.37,51.11076923076923,53.85153846153846,56.59230769230769,59.33307692307692,62.073846153846155,64.81461538461538,67.55538461538461,70.29615384615384,73.03692307692307,75.7776923076923,78.51846153846154,81.25923076923077,{"y":84,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.37,50.25153846153846,52.13307692307692,54.01461538461538,55.896153846153844,57.777692307692305,59.65923076923077,61.54076923076923,63.42230769230769,65.30384615384615,67.1853846153846,69.06692307692308,70.94846153846154,{"y":72.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.37,49.26461538461538,50.15923076923077,51.05384615384615,51.94846153846154,52.84307692307692,53.737692307692306,54.63230769230769,55.526923076923076,56.42153846153846,57.316153846153846,58.21076923076923,59.105384615384615,{"y":60,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.07,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.08,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.82,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.35,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.2,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.33,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.01,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.82,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.08,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.12,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.64,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.31,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.37,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >